PharmAbcine is a clinical stage public company in KOSDAQ market(208340) and focusing on next generation therapeutics for cancer patients. Olinvacimab is in several clinical trials globally as single but also combination with Keytruda with MERCK. PMC-309, anti-VISTA neutralizing antibody and PMC-402, anti-TIE2 agonizing antibody are in oncology program and will be in Phase I in 2021.
Company HQ State:
Company HQ Country:
Korea - South Korea
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):